IL151888A0 - Granulated particles with masked taste - Google Patents
Granulated particles with masked tasteInfo
- Publication number
- IL151888A0 IL151888A0 IL15188801A IL15188801A IL151888A0 IL 151888 A0 IL151888 A0 IL 151888A0 IL 15188801 A IL15188801 A IL 15188801A IL 15188801 A IL15188801 A IL 15188801A IL 151888 A0 IL151888 A0 IL 151888A0
- Authority
- IL
- Israel
- Prior art keywords
- pellets
- granulated particles
- active compound
- pharmaceutically active
- masked taste
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Seasonings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT5242000 | 2000-03-28 | ||
PCT/EP2001/003409 WO2001072284A1 (fr) | 2000-03-28 | 2001-03-26 | Particules granulees a masquage de gout |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151888A0 true IL151888A0 (en) | 2003-04-10 |
Family
ID=3675949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15188801A IL151888A0 (en) | 2000-03-28 | 2001-03-26 | Granulated particles with masked taste |
Country Status (17)
Country | Link |
---|---|
US (3) | US20030099715A1 (fr) |
EP (1) | EP1267840B1 (fr) |
KR (1) | KR20030011797A (fr) |
AT (1) | ATE432691T1 (fr) |
AU (2) | AU6381201A (fr) |
BR (1) | BR0109544A (fr) |
CA (1) | CA2403757A1 (fr) |
DE (1) | DE60138876D1 (fr) |
DK (1) | DK1267840T3 (fr) |
HK (1) | HK1051148A1 (fr) |
HR (1) | HRP20020781A2 (fr) |
IL (1) | IL151888A0 (fr) |
IS (1) | IS6553A (fr) |
MX (1) | MXPA02009587A (fr) |
NZ (1) | NZ521368A (fr) |
WO (1) | WO2001072284A1 (fr) |
ZA (1) | ZA200207737B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168228B2 (en) | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
WO2006030297A1 (fr) * | 2004-09-17 | 2006-03-23 | Ranbaxy Laboratories Limited | Granules au gout masque comprenant de la clarithromycine, des hydrocolloides et un revetement |
FR2911506B1 (fr) * | 2007-01-18 | 2009-07-03 | Ceva Sante Animale Sa | Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees |
US8999395B2 (en) | 2007-02-09 | 2015-04-07 | Ceva Sante Animale | Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions |
US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
WO2015166473A1 (fr) * | 2014-05-01 | 2015-11-05 | Sun Pharmaceutical Industries Limited | Compositions en suspension à libération prolongée |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
US20180104197A9 (en) | 2014-05-01 | 2018-04-19 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
WO2016016845A1 (fr) | 2014-07-30 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Emballage à double chambre |
WO2016154313A1 (fr) * | 2015-03-24 | 2016-09-29 | Zywie, Llc | Compositions pharmaceutiques liquides à forte charge pour administration par voie orale |
US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331803A (en) * | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
JPS59104326A (ja) * | 1982-12-04 | 1984-06-16 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
JPS61103890A (ja) * | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシンa誘導体 |
US4640910A (en) * | 1985-11-12 | 1987-02-03 | Abbott Laboratories | Erythromycin A silylated compounds and method of use |
US4833236A (en) * | 1986-05-02 | 1989-05-23 | Taisho Pharmaceutical Co., Ltd. | Erythromycin derivatives |
DE3782994T2 (de) * | 1986-09-18 | 1993-04-08 | Taisho Pharma Co Ltd | Erythromycin-a-derivate und verfahren zu ihrer herstellung. |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
US5811088A (en) * | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
KR880009960A (ko) * | 1987-02-24 | 1988-10-06 | 데이빗 로버츠 | 화학적 화합물 |
US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
US5874164A (en) * | 1988-03-14 | 1999-02-23 | Nextec Applications, Inc. | Barrier webs having bioactive surfaces |
US6040251A (en) * | 1988-03-14 | 2000-03-21 | Nextec Applications Inc. | Garments of barrier webs |
US5856245A (en) * | 1988-03-14 | 1999-01-05 | Nextec Applications, Inc. | Articles of barrier webs |
US4925675A (en) * | 1988-08-19 | 1990-05-15 | Himedics, Inc. | Erythromycin microencapsulated granules |
US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
US5085864A (en) * | 1989-10-30 | 1992-02-04 | Abbott Laboratories | Injectable formulation for lipophilic drugs |
IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
WO1992006991A1 (fr) * | 1990-10-15 | 1992-04-30 | Taisho Pharmaceutical Co., Ltd. | Erythromycine modifiee en 2' ou derive de cette substance |
KR0166096B1 (ko) * | 1990-11-28 | 1999-01-15 | 우에하라 아키라 | 6-0-메틸에리쓰로마이신 a 유도체 |
US5599556A (en) * | 1991-12-31 | 1997-02-04 | Abbott Laboratories | Prolamine coatings for taste masking |
JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
TW276996B (fr) * | 1992-04-24 | 1996-06-01 | Astra Ab | |
US6043225A (en) * | 1992-06-12 | 2000-03-28 | Board Of Regents Of The University Of Washington | Diagnosis and treatment of arterial chlamydial granuloma |
US5811547A (en) * | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
US5356634A (en) * | 1992-11-13 | 1994-10-18 | Eastman Chemical Company | Controlled-release delivery system |
ATE181672T1 (de) * | 1993-04-28 | 1999-07-15 | Takeda Chemical Industries Ltd | Geschmacksmaskierte feste zubereitung und verfahren zur herstellung |
FR2713226B1 (fr) * | 1993-12-03 | 1996-01-05 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
ES2199981T3 (es) * | 1994-02-16 | 2004-03-01 | Abbott Laboratories | Modo de preparacion de formulaciones farmaceuticas de particulas finas. |
EP0758549A4 (fr) * | 1994-04-26 | 1997-07-02 | Nobuhiro Narita | Composition medicinale servant de medicament contre le cancer bronchopulmonaire "non a petites cellules" |
EP0689840A1 (fr) * | 1994-06-28 | 1996-01-03 | Spirig Ag Pharmazeutische Präparate | Nouvelle composition pharmaceutique contenant de l'érythromycine base libre |
US5498424A (en) * | 1994-11-30 | 1996-03-12 | Klein; Ira | Method of treating obesity |
US5760010A (en) * | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
US6379651B1 (en) * | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
US5972373A (en) * | 1995-05-02 | 1999-10-26 | Taisho Pharmaceutical Co., Ltd. | Taste masking pharmaceutical composition for oral administration |
US5786338A (en) * | 1995-06-28 | 1998-07-28 | Klein; Ira | Method of treating hypercholesterolemia with a macrolide antibiotic |
US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
US5919489A (en) * | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5885601A (en) * | 1996-04-05 | 1999-03-23 | Family Health International | Use of macrolide antibiotics for nonsurgical female sterilization and endometrial ablation |
US5808017A (en) * | 1996-04-10 | 1998-09-15 | Abbott Laboratories | Process for preparing erythromycin A oxime |
US5958888A (en) * | 1996-07-02 | 1999-09-28 | Merial, Inc. | Water miscible macrolide solutions |
US5844105A (en) * | 1996-07-29 | 1998-12-01 | Abbott Laboratories | Preparation of crystal form II of clarithromycin |
US5858986A (en) * | 1996-07-29 | 1999-01-12 | Abbott Laboratories | Crystal form I of clarithromycin |
US5853740A (en) * | 1996-08-07 | 1998-12-29 | Abbott Laboratories | Delivery system for pharmaceutical agents encapsulated with oils |
US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
US6400374B2 (en) * | 1996-09-18 | 2002-06-04 | Eyematic Interfaces, Inc. | Video superposition system and method |
GB2318511A (en) * | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US5945405A (en) * | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
US6551632B2 (en) * | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
ES2303351T3 (es) * | 1997-04-01 | 2008-08-01 | Thomas Julius Borody | Metodos y composiciones para tratar enfermedades intestinales inflamatorias. |
US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6406880B1 (en) * | 1997-05-02 | 2002-06-18 | Integrated Research Technology, Llc | Betaines as adjuvants to susceptibility testing and antimicrobial therapy |
AU729529B2 (en) * | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
US6054133A (en) * | 1997-07-10 | 2000-04-25 | The Regents Of The University Of California | Anti-microbial targeting for intracellular pathogens |
SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
EP0895999A1 (fr) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | Macrolides antibiotiques substitués C"-4 |
US6174865B1 (en) * | 1997-09-25 | 2001-01-16 | Ira Klein | Method of treating hypertriglyceridemia with an erythromycin compound |
US5928174A (en) * | 1997-11-14 | 1999-07-27 | Acrymed | Wound dressing device |
US5955440A (en) * | 1998-03-27 | 1999-09-21 | Abbott Laboratories | Macrolide LHRH antagonists |
US5972898A (en) * | 1998-03-27 | 1999-10-26 | Abbott Laboratories | 3',3-N-bis-substituted macrolide LHRH antagonists |
DE19814257A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
HRP980189B1 (en) * | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
US6015803A (en) * | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
US6322532B1 (en) * | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
US20020107174A1 (en) * | 1998-07-02 | 2002-08-08 | Erik J. Paus | Composition comprising endotoxin neutralizing protein and derivatives and uses thereof |
US6239112B1 (en) * | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US6264991B1 (en) * | 1998-08-18 | 2001-07-24 | Southern Research Institute | Compositions and methods for treating intracellular infections |
US20020106357A1 (en) * | 1998-09-24 | 2002-08-08 | Ira Shafran | Crohn's disease treatment methods |
AU760884B2 (en) * | 1998-10-20 | 2003-05-22 | Russinsky Limited | Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity |
US6357323B2 (en) * | 1998-11-16 | 2002-03-19 | Yuan-Ching Chi | Wrench |
US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
IN190017B (fr) * | 1999-01-25 | 2003-05-31 | Panacea Biotech Ltd | |
IL133077A0 (en) * | 1999-01-29 | 2001-03-19 | Pfizer Prod Inc | Azithromycin combination for emesis control in dogs |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
FR2793690B1 (fr) * | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
SI20244A (sl) * | 1999-05-19 | 2000-12-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Granulacija v talini |
PT1194124E (pt) * | 1999-06-11 | 2004-02-27 | Ranbaxy Lab Ltd | Composicoes de sabor mascarado |
CA2282066C (fr) * | 1999-06-29 | 2010-09-07 | Smithkline Beecham Corporation | Methodes d'utilisation de composes de quinolone contre des bacteries pathogenes atypiques dans les voies respiratoires superieures |
US6228400B1 (en) * | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
US20020068761A1 (en) * | 1999-10-04 | 2002-06-06 | Bernstein Lawrence R. | Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
CZ20021999A3 (cs) * | 1999-12-16 | 2003-02-12 | Teva Pharmaceutical Industries Ltd. | Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV |
PL356645A1 (en) * | 2000-01-11 | 2004-06-28 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs |
AU2578701A (en) * | 2000-02-29 | 2001-09-12 | Teva Pharma | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
AU771825B2 (en) * | 2000-03-15 | 2004-04-01 | Hanmi Pharm. Co., Ltd. | Method of preparing clarithromycin of form II crystals |
US20010041706A1 (en) * | 2000-03-24 | 2001-11-15 | Synold Timothy W. | Blockade of taxane metabolism |
US6761895B2 (en) * | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
AU5967101A (en) * | 2000-05-10 | 2001-11-20 | Rtp Pharma Inc | Media milling |
US20020042394A1 (en) * | 2000-05-31 | 2002-04-11 | Hogenkamp Henricus P.C. | Cobalamin compounds useful as antibiotic agents and as imaging agents |
US20020013270A1 (en) * | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
CN1176935C (zh) * | 2000-06-20 | 2004-11-24 | 王新华 | 克拉霉素2′-单丙酸酯十二烷基硫酸盐制备及其药用 |
US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
CA2417389C (fr) * | 2000-07-27 | 2012-05-29 | Rutgers, The State University | Polyesters et polyamides therapeutiques |
US20020032245A1 (en) * | 2000-07-27 | 2002-03-14 | Lyn Hughes | Resinate composition |
US20020115621A1 (en) * | 2000-08-07 | 2002-08-22 | Wei-Gu Su | Macrolide antibiotics |
IN192748B (fr) * | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
US6452879B1 (en) * | 2000-09-29 | 2002-09-17 | Fujitsu Limited | Optical storage apparatus |
-
2001
- 2001-03-26 DK DK01938048T patent/DK1267840T3/da active
- 2001-03-26 NZ NZ521368A patent/NZ521368A/en not_active IP Right Cessation
- 2001-03-26 IL IL15188801A patent/IL151888A0/xx unknown
- 2001-03-26 CA CA002403757A patent/CA2403757A1/fr not_active Abandoned
- 2001-03-26 BR BR0109544-7A patent/BR0109544A/pt not_active Application Discontinuation
- 2001-03-26 AU AU6381201A patent/AU6381201A/xx active Pending
- 2001-03-26 AU AU2001263812A patent/AU2001263812B2/en not_active Expired
- 2001-03-26 WO PCT/EP2001/003409 patent/WO2001072284A1/fr active IP Right Grant
- 2001-03-26 AT AT01938048T patent/ATE432691T1/de not_active IP Right Cessation
- 2001-03-26 US US10/240,003 patent/US20030099715A1/en not_active Abandoned
- 2001-03-26 KR KR1020027012288A patent/KR20030011797A/ko active Search and Examination
- 2001-03-26 MX MXPA02009587A patent/MXPA02009587A/es not_active Application Discontinuation
- 2001-03-26 DE DE60138876T patent/DE60138876D1/de not_active Expired - Lifetime
- 2001-03-26 EP EP01938048A patent/EP1267840B1/fr not_active Expired - Lifetime
-
2002
- 2002-09-18 IS IS6553A patent/IS6553A/is unknown
- 2002-09-26 ZA ZA200207737A patent/ZA200207737B/en unknown
- 2002-09-27 HR HRP20020781 patent/HRP20020781A2/hr not_active Application Discontinuation
-
2003
- 2003-05-19 HK HK03103528.2A patent/HK1051148A1/xx not_active IP Right Cessation
-
2005
- 2005-06-03 US US11/145,354 patent/US20050220871A1/en not_active Abandoned
-
2007
- 2007-10-22 US US11/876,214 patent/US20080095855A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001072284A1 (fr) | 2001-10-04 |
US20050220871A1 (en) | 2005-10-06 |
MXPA02009587A (es) | 2003-05-14 |
HRP20020781A2 (en) | 2004-12-31 |
BR0109544A (pt) | 2003-06-10 |
NZ521368A (en) | 2004-05-28 |
EP1267840B1 (fr) | 2009-06-03 |
DE60138876D1 (de) | 2009-07-16 |
AU6381201A (en) | 2001-10-08 |
DK1267840T3 (da) | 2009-09-07 |
US20080095855A1 (en) | 2008-04-24 |
ATE432691T1 (de) | 2009-06-15 |
US20030099715A1 (en) | 2003-05-29 |
KR20030011797A (ko) | 2003-02-11 |
ZA200207737B (en) | 2003-05-08 |
EP1267840A1 (fr) | 2003-01-02 |
CA2403757A1 (fr) | 2001-10-04 |
IS6553A (is) | 2002-09-18 |
AU2001263812B2 (en) | 2004-09-23 |
HK1051148A1 (en) | 2003-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1051148A1 (en) | Granulated particles with masked taste | |
IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
CA2340052A1 (fr) | Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane | |
WO2001085257A3 (fr) | Compositions d'antagoniste opioide et formes de dosage | |
PH26317A (en) | Modified release gemfibrozil composition | |
AU2003231126A1 (en) | Chewable soft capsule | |
BG105061A (en) | Enteric coated pharmaceutical composition and method of manufacturing | |
WO2007000778A3 (fr) | Compositions pharmaceutiques a liberation modifiee et leurs procedes | |
CA2411754A1 (fr) | Acide 4-¬(4-chloro-2-hydroxybenzoyl)amino|butanoique et compositions d'administration d'agents actifs | |
CA2297083A1 (fr) | Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques | |
WO2006050002A3 (fr) | Compositions destinees a l'administration controlee de composes pharmaceutiquement actifs | |
WO2002019969A3 (fr) | Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs | |
WO2002008217A3 (fr) | DERIVES DE LA COUMARINE UTILISES COMME INHIBITEUR DU TNF$g(a) | |
HRP20050342B1 (hr) | Farmaceutska formulacija olanzapina | |
GEP20043285B (en) | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections | |
AU2003221524A1 (en) | Administration form for oral administration of active ingredients, vitamins and/or nutrients | |
CA2488422A1 (fr) | Composition medicinale solide, stabilisee, a base de ramosetron, pour administration orale | |
ES2185452A1 (es) | Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion. | |
WO2005065639A3 (fr) | Nouvelles compositions pharmaceutiques | |
WO2005009410A3 (fr) | Compositions pharmaceutiques a revetement gonflant | |
WO2003020200A8 (fr) | Nouveau compose pharmaceutique et procedes de fabrication et d'utilisation de ce compose | |
WO2002015892A3 (fr) | Combinaisons | |
TW200420304A (en) | Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction | |
GB2426707A (en) | A stable parental formulation of levomepromazine and a method for stabilizing said formulation | |
WO2003020304A3 (fr) | Compose modulateur d'inflammation |